Drugs / MW032
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04798326 | Jun 2019 → Jan 2020 | bone neoplasm | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04812509 | Mar 2020 → Apr 2021 | bone neoplasm | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04798326 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032)” NCT04812509 ↗ |
| Route | Subcutaneous | “Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.” NCT04798326 ↗ |